Efficacy and safety of anlotinib plus XELOX regimen as first-line therapy for mCRC: a single-arm, multicenter, phase II study (ALTER-C-001).
Frontiers in oncology（2023）
摘要
chictr.org.cn, identifier ChiCTR1900028417.
更多查看译文
关键词
anlotinib, XELOX, metastatic colorectal cancer, efficacy, safety, first-line therapy
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要